면역 세포 공학 시장 규모, 점유율 및 동향 분석 보고서 : 세포 유형별, 제품별, 적응 질환별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Immune Cell Engineering Market Summary

The global immune cell engineering market size was estimated at USD 4.19 billion in 2025 and is anticipated to reach USD 14.31 billion by 2033, growing at a CAGR of 17.3% from 2026 to 2033. This growth is driven by the increasing adoption of engineered immune cell therapies for cancer and autoimmune disease treatment, rising investments in cell and gene therapy research, and continuous advancements in technologies such as CRISPR and CAR-T cell engineering.

Advancements in Gene-Editing and Cell Therapy Technologies

Advancements in gene-editing and cell therapy technologies are driving the immune cell engineering market by enabling more precise and personalized immunotherapies. Tools such as CRISPR-Cas9, TALENs, and improved viral and non-viral delivery systems enhance the genetic modification of immune cells, such as T cells and NK cells, thereby improving their ability to target cancer cells. In addition, innovations in CAR-T and TCR-T therapies are increasing treatment efficacy, reducing off-target effects, and expanding applications to solid tumors and autoimmune diseases.

Global Immune Cell Engineering Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immune cell engineering market report based on cell type, product, disease indication, end-use, and region:

• Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
• T Cells
• NK Cells
• Dendritic Cells
• Tumor Cells
• Stem Cells
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments
• Software
• Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Diseases
• Respiratory Diseases
• Infectious Diseases
• Cancer
• Neurological Diseases
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Academic & Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Cell Type
  • 1.2.2. Product
  • 1.2.3. Disease Indication
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Impact Analysis
    • 3.3.1.1. Advancements in gene-editing and cell therapy technologies
    • 3.3.1.2. Expanding clinical trials for engineered immune cell therapies
    • 3.3.1.3. Rising prevalence of cancer and chronic diseases
    • 3.3.1.4. Increasing adoption of personalized medicine
  • 3.3.2. Market Restraint Impact Analysis
    • 3.3.2.1. High manufacturing and development costs
    • 3.3.2.2. Safety and clinical limitations
  • 3.3.3. Market Opportunity Analysis
  • 3.3.4. Market Challenge Analysis
• 3.4. Case Study Insights
• 3.5. Business Environment Analysis
  • 3.5.1. PESTLE Analysis
  • 3.5.2. PORTER'S Five Forces Analysis

Chapter 4. Cell Type Business Analysis

• 4.1. Cell Type Segment Dashboard
• 4.2. Global Immune Cell Engineering Market Cell Type, Movement Analysis
• 4.3. Global Immune Cell Engineering Market Size & Trend Analysis, by Cell Type, 2021 to 2033 (USD Million)
• 4.4. T Cells
  • 4.4.1. Global T Cells Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. NK Cells
  • 4.5.1. Global NK Cells Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Dendritic Cells
  • 4.6.1. Global Dendritic Cells Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Tumor Cells
  • 4.7.1. Global Tumor Cells Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Stem Cells
  • 4.8.1. Global Stem Cells Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Product Segment Dashboard
• 5.2. Global Immune Cell Engineering Market Product, Movement Analysis
• 5.3. Global Immune Cell Engineering Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Global Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Instruments
  • 5.5.1. Global Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Software
  • 5.6.1. Global Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Disease Indication Business Analysis

• 6.1. Disease Indication Segment Dashboard
• 6.2. Global Immune Cell Engineering Market Disease Indication, Movement Analysis
• 6.3. Global Immune Cell Engineering Market Size & Trend Analysis, by Disease Indication, 2021 to 2033 (USD Million)
• 6.4. Cardiovascular Diseases
  • 6.4.1. Global Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Respiratory Diseases
  • 6.5.1. Global Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Infectious Diseases
  • 6.6.1. Global Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Cancer
  • 6.7.1. Global Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Neurological Diseases
  • 6.8.1. Global Neurological Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Immune Cell Engineering Market End Use, Movement Analysis
• 7.3. Global Immune Cell Engineering Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Hospitals & Clinics
  • 7.5.1. Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Global Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Immune Cell Engineering Market: Regional Estimates and Trend Analysis, by Cell Type, Product, Disease Indication & End Use

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 8.3. North America
  • 8.3.1. North America Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Immune Cell Engineering Market, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Immune Cell Engineering Market, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Immune Cell Engineering Market, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Immune Cell Engineering Market, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Immune Cell Engineering Market, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Immune Cell Engineering Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2025
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Merck KGaA
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Danaher Corporation
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Lonza
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Miltenyi Biotec
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Takara Bio Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Sartorious AG
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Agilent Technologies, Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Bio-Techne
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Bio-Rad Laboratories, Inc.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives